These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23518784)

  • 21. Internet highs--seizures after consumption of synthetic cannabinoids purchased online.
    Tofighi B; Lee JD
    J Addict Med; 2012 Sep; 6(3):240-1. PubMed ID: 22824736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acute Psychosis after Consumption of Synthetic Cannabinoids].
    Mörkl S; Blesl C; Wurm WE; Tmava A
    Fortschr Neurol Psychiatr; 2016 Mar; 84(3):150-4. PubMed ID: 27029042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Changing Drug Culture: Emerging Drugs of Abuse and Legal Highs.
    Albertson TE; Chenoweth JA; Colby DK; Sutter ME
    FP Essent; 2016 Feb; 441():18-24. PubMed ID: 26881769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic cannabinoids as drugs of abuse.
    Ashton JC
    Curr Drug Abuse Rev; 2012 Jun; 5(2):158-68. PubMed ID: 22530798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rhabdomyolysis after low-dose quetiapine in a patient with Parkinson's disease with drug-induced psychosis: a case report.
    Stephani C; Trenkwalder C
    Mov Disord; 2010 Apr; 25(6):790-1. PubMed ID: 20198646
    [No Abstract]   [Full Text] [Related]  

  • 26. Synthetic cannabinoid use: recognition and management.
    Castellanos D; Thornton G
    J Psychiatr Pract; 2012 Mar; 18(2):86-93. PubMed ID: 22418399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute Rhabdomyolysis Following Synthetic Cannabinoid Ingestion.
    Adedinsewo DA; Odewole O; Todd T
    N Am J Med Sci; 2016 Jun; 8(6):256-8. PubMed ID: 27500131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe fenitrothion poisoning complicated by rhabdomyolysis in psychiatric patient.
    Futagami K; Hirano N; Iimori E; Motomura K; Ide M; Kataoka Y; Araki H; Gomita Y; Oishi R
    Acta Med Okayama; 2001 Apr; 55(2):129-32. PubMed ID: 11332199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
    Kourouni I; Mourad B; Khouli H; Shapiro JM; Mathew JP
    JAMA Netw Open; 2020 Jul; 3(7):e208516. PubMed ID: 32687586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report.
    Alhassan A; Prahad SR; Burk BG; Fargason RE; Birur B
    Psychopharmacol Bull; 2024 Mar; 54(1):33-39. PubMed ID: 38449474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Differential approaches to the treatment of acute psychosis due to the use of synthetic cannabinoids].
    Kekelidze ZI; Klimenko TV; Kozlov AA; Shakhova SM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(12):21-26. PubMed ID: 29376979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review.
    Alves VL; Gonçalves JL; Aguiar J; Teixeira HM; Câmara JS
    Crit Rev Toxicol; 2020 May; 50(5):359-382. PubMed ID: 32530350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review.
    Armstrong F; McCurdy MT; Heavner MS
    Pharmacotherapy; 2019 Apr; 39(4):508-513. PubMed ID: 30811628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues.
    Schep LJ; Slaughter RJ; Hudson S; Place R; Watts M
    Hum Exp Toxicol; 2015 May; 34(5):557-60. PubMed ID: 25233895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
    Bassir Nia A; Mann CL; Spriggs S; DeFrancisco DR; Carbonaro S; Parvez L; Galynker II; Perkel CA; Hurd YL
    J Clin Psychiatry; 2019 Jul; 80(4):. PubMed ID: 31265768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic cannabinoid overdose in a 20-year-old male US soldier.
    Berry-Cabán CS; Ee J; Ingram V; Berry CE; Kim EH
    Subst Abus; 2013; 34(1):70-2. PubMed ID: 23327506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospitalisation associated with use of the synthetic cannabinoid K2.
    Glue P; Al-Shaqsi S; Hancock D; Gale C; Strong B; Schep L
    N Z Med J; 2013 Jun; 126(1377):18-23. PubMed ID: 23831873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose venlafaxine-induced severe rhabdomyolysis: a case report.
    Huang SS; Yang HY; Lin YC; Chan CH
    Gen Hosp Psychiatry; 2012; 34(4):436.e5-7. PubMed ID: 22459996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids.
    Loeffler G; Delaney E; Hann M
    Brain Res Bull; 2016 Sep; 126(Pt 1):8-28. PubMed ID: 27108542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
    Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V
    Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.